The pharmaceutical industry is undergoing dramatic changes in its market and regulatory environments in the United States and abroad. While the Food and Drug Administration has been slow to finalize several key rulemakings, the industry is drawing more attention from Congress and the media, as issues such as the Trans-Pacific Partnership (TPP) and the opioid epidemic have come into the spotlight. These public debates are likely to guide legislative and regulatory agendas for the remainder of this year and throughout next year.
The impending presidential election also brings a high degree of uncertainty, as the Obama administration has been the primary driver of industry policy in recent years. As we reach the final stages of election fever, we’ve taken stock of four key drivers of uncertainty in the pharmaceutical market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
